Neuland Laboratories is an Indian API manufacturer and CDMO that develops and commercializes small-molecule APIs, intermediates and peptide APIs, operating three cGMP manufacturing facilities (USFDA/EMA/PMDA audited), a 428-strong scientific R&D team and global commercial presence across 80+ countries with total reactor volume of 1,218,000 liters and ~2,131 employees.

Q3FY26 results show total income of Rs.447.8 crore (+11.4% YoY) with EBITDA of Rs.85 crore at 19% margin (down 350bps YoY) and PAT of Rs.40.4 crore (-60% YoY); 9MFY26 capex was Rs.254 crore while net debt improved to a net cash position of Rs.(202.6) crore, reflecting heavy investment alongside deleveraging.

The company is actively shifting mix from lower-margin Prime APIs toward higher-margin Specialty and CMS (CDMO) work: CMS accounted for 61% of Q3 revenue and 54% of 9M revenue, supported by 98 active CMS projects and an explicit peptide manufacturing push, positioning Neuland to capture the fast-growing peptide API market forecast to reach ~$14bn by 2030.

Key operational risks and near-term drivers include product and customer concentration (CMS top-5 customers account for north of 90% of CMS revenue), working capital elevated at ~145 days driven by inventory and receivables, and quarter-to-quarter lumpiness from large individual CMS shipments and customer-side operational timing (for example paliperidone shipment delays).